Skip to main content


Health

Novartis says that it now seeks approval for serelaxin. Researchers say that in a study of 1,161 patients, the drug cut deaths from any cause at six months by 37 percent and led to a marked reduction in worsening of heart failure during hospitalization.
541 of 1528




Newsletter Sign Up

Daily Readings

Gospel, John 11:19-27
and many Jews had come to Martha and Mary to comfort them about ... Read More

Saint of the Day

July 29 Saint of the Day

St. Martha
July 29: "Jesus loved Martha and Mary and Lazarus." This unique ... Read More